{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:00:38Z","timestamp":1780552838057,"version":"3.54.1"},"reference-count":423,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005688","name":"The University of Texas at Austin Graduate School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029566","name":"Phi Lambda Sigma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008562","name":"University of Texas at Austin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.addr.2025.115715","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:12:59Z","timestamp":1760501579000},"page":"115715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Composition, stabilization and delivery of virus-based vaccines: considerations to break free of the cold chain"],"prefix":"10.1016","volume":"227","author":[{"given":"Amaka J.","family":"Epoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jailen H.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irnela","family":"Bajrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Croyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115715_bb0005","series-title":"Essential Human Virology","first-page":"145","article-title":"Vaccines, antivirals, and the beneficial uses of viruses","author":"Louten","year":"2022"},{"key":"10.1016\/j.addr.2025.115715_bb0010","series-title":"Early Efforts at Control\u202f: variolation, Vaccination, and Isolation and Quarantine","first-page":"245","author":"Fenner","year":"1988"},{"key":"10.1016\/j.addr.2025.115715_bb0015","unstructured":"USFDA. Vaccines Licensed for Use in the United States. 2025 [accessed 10\/06\/25]; Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states."},{"key":"10.1016\/j.addr.2025.115715_bb0020","unstructured":"Johns Hopkins Institute for Vaccine Safety, Components of Vaccines, accessed 10\/06\/25, 2025. Available from:https:\/\/www.vaccinesafety.edu\/components\/."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb0030","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/14760584.2017.1383159","article-title":"An overview of FDA-approved vaccines & their innovators","volume":"16","author":"Griesenauer","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jpids\/piy082","article-title":"Vaccine hesitancy, history, and human nature: the 2018 Stanley a","volume":"8","author":"Marshall","year":"2019","journal-title":"Plotkin Lecture. J. Pediatric Infect Dis. Soc."},{"key":"10.1016\/j.addr.2025.115715_bb0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: historical successes and current challenges","volume":"479-480","author":"Minor","year":"2015","journal-title":"Virology"},{"issue":"20","key":"10.1016\/j.addr.2025.115715_bb0045","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1093\/nar\/12.20.7787","article-title":"Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine","volume":"12","author":"Cann","year":"1984","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10875-019-00642-3","article-title":"Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity","volume":"39","author":"P\u00f6yh\u00f6nen","year":"2019","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb0060","series-title":"Chapter 9 - Vaccine Use in Immunocompromised Adults: Challenges and Solutions, in Vaccinations, G.A. Poland","first-page":"139","author":"Whitaker","year":"2019"},{"key":"10.1016\/j.addr.2025.115715_bb0065","article-title":"Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: a comprehensive review and practical guide","volume":"13","author":"Blanchard-Rohner","year":"2021","journal-title":"Front. Immunol."},{"issue":"28","key":"10.1016\/j.addr.2025.115715_bb0070","first-page":"241","article-title":"Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries","volume":"78","year":"2003","journal-title":"Wkly Epidemiol. Rec."},{"issue":"40","key":"10.1016\/j.addr.2025.115715_bb0075","first-page":"349","article-title":"WHO position paper","volume":"78","author":"Yellow fever vaccine","year":"2003","journal-title":"Wkly Epidemiol. Rec."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11020271","article-title":"Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes","volume":"11","author":"Elveborg","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.addr.2025.115715_bb0085","first-page":"45","article-title":"Inactivated viral vaccines","author":"Sanders","year":"2014","journal-title":"Vaccine Analysis: Strategies, Principles, and Control"},{"issue":"25","key":"10.1016\/j.addr.2025.115715_bb0090","first-page":"699","article-title":"Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent Oral poliovirus vaccine - worldwide, 2013-2016","volume":"64","year":"2015","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2243","article-title":"Influenza vaccines: Past, present, and future","volume":"32","author":"Kim","year":"2022","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40506-020-00242-5","article-title":"Japanese encephalitis vaccines","volume":"12","author":"Satchidanandam","year":"2020","journal-title":"Curr. Treat. Options Infect. Dis."},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb0105","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/21645515.2020.1769389","article-title":"Hepatitis a vaccination","volume":"16","author":"Zhang","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/vaccines7020054","article-title":"New rabies vaccines for use in humans","volume":"7","author":"Ertl","year":"2019","journal-title":"Vaccines (Basel)."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-0716-1892-9_2","article-title":"Progress in the development of structure-based vaccines","volume":"2412","author":"Thomas","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2025.115715_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: from whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081072","article-title":"Platforms for production of protein-based vaccines: from classical to next-generation strategies","volume":"11","author":"Cid","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2025.115715_bb0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-3387-7_3","article-title":"Principles of vaccination","volume":"1403","author":"Zepp","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0145","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/vaccines11030507","article-title":"mRNA-based vaccine for COVID-19: they are new but not unknown!","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12985-023-02023-0","article-title":"Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines","volume":"20","author":"Guo","year":"2023","journal-title":"Virol. J."},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb0155","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","article-title":"Recent advancement in mRNA vaccine development and applications","volume":"15","author":"Al Fayez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115715_bb0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines."},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb0175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4161\/hv.8476","article-title":"Sex differences in injection site reactions with human vaccines","volume":"5","author":"Cook","year":"2009","journal-title":"Hum. Vaccin."},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0180","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s12272-017-0969-z","article-title":"Vaccine adjuvants: smart components to boost the immune system","volume":"40","author":"Bastola","year":"2017","journal-title":"Arch. Pharm. Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int. Anesthesiol. Clin."},{"key":"10.1016\/j.addr.2025.115715_bb0190","unstructured":"Abbas, A.K., A.H. Lichtman, and S. Pillai, Cellular and Molecular Immunology E-Book: Cellular and Molecular Immunology E-Book. 2021: Elsevier."},{"key":"10.1016\/j.addr.2025.115715_bb0205","series-title":"Kuby Immunology. 4th ed. Immunology","author":"Goldsby","year":"2000"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0195","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","article-title":"Present yourself! By MHC class I and MHC class II molecules","volume":"37","author":"Rock","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb0200","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In vivo CD4(+) T cell differentiation and function: revisiting the Th1\/Th2 paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2019.12.005","article-title":"Cross-presentation of exogenous antigens on MHC I molecules","volume":"64","author":"Colbert","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"22","key":"10.1016\/j.addr.2025.115715_bb0215","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk\/benefit assessment","volume":"39","author":"Custers","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0220","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/cei.12829","article-title":"The life cycle of a T cell after vaccination - where does immune ageing strike?","volume":"187","author":"Kim","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0235","article-title":"Engineering vaccines for tissue-resident memory T cells","volume":"4","author":"Knight","year":"2021","journal-title":"Adv. Ther (Weinh)."},{"key":"10.1016\/j.addr.2025.115715_bb0240","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3389\/fimmu.2018.01574","article-title":"A systematic review: the role of resident memory T cells in infectious diseases and their relevance for vaccine development","volume":"9","author":"Muruganandah","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0245","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0047-7206(74)90001-6","article-title":"Application of the negative staining-carbon technique to the study of virus particles and their components by electron microscopy","volume":"5","author":"Horne","year":"1974","journal-title":"Micron (1969)"},{"issue":"16","key":"10.1016\/j.addr.2025.115715_bb0250","first-page":"787","article-title":"A classification of virus particles based on morphology","volume":"89","author":"Almeida","year":"1963","journal-title":"Can Med. Assoc. J."},{"key":"10.1016\/j.addr.2025.115715_bb0255","series-title":"Virology: Principles and Applications","author":"Carter","year":"2007"},{"key":"10.1016\/j.addr.2025.115715_bb0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.coviro.2021.09.006","article-title":"Structure of filamentous viruses","volume":"51","author":"Zanotti","year":"2021","journal-title":"Curr. Opin. Virol."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0265","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40588-016-0041-7","article-title":"Filamentous Influenza Viruses","volume":"3","author":"Badham","year":"2016","journal-title":"Curr. Clin. Microbiol. Rep."},{"issue":"44","key":"10.1016\/j.addr.2025.115715_bb0270","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1073\/pnas.1105770108","article-title":"Electron cryotomography of measles virus reveals how matrix protein coats the ribonucleocapsid within intact virions","volume":"108","author":"Liljeroos","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0275","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/jvi.1.2.415-429.1967","article-title":"Immuno-electron microscopy of the morphogenesis of mumps virus","volume":"1","author":"Duc-Nguyen","year":"1967","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/jvi.1.1.152-170.1967","article-title":"Structure and development of rabies virus in tissue culture","volume":"1","author":"Hummeler","year":"1967","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0285","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.1120453109","article-title":"Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography","volume":"109","author":"Bharat","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/smvy.1995.0036","article-title":"The structure of parvoviruses","volume":"6","author":"Agbandje","year":"1995","journal-title":"Semin. Virol."},{"issue":"Pt 11","key":"10.1016\/j.addr.2025.115715_bb0295","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1099\/0022-1317-71-11-2483","article-title":"Structure, function and evolution of picornaviruses","volume":"71","author":"Stanway","year":"1990","journal-title":"J. Gen. Virol."},{"issue":"16","key":"10.1016\/j.addr.2025.115715_bb0300","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1039\/D1NR08064D","article-title":"Filamentous bacteriophages, natural nanoparticles, for viral vaccine strategies","volume":"14","author":"Wang","year":"2022","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0305","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1128\/am.20.3.497-504.1970","article-title":"Experience with electron microscopy in the differential diagnosis of smallpox","volume":"20","author":"Long","year":"1970","journal-title":"Appl. Microbiol."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0310","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2022.12723","article-title":"Mimiviruses: Giant viruses with novel and intriguing features (review)","volume":"25","author":"Kalafati","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.addr.2025.115715_bb0315","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2021.04.012","article-title":"Structure and physiology of giant DNA viruses","volume":"49","author":"Dos Santos Oliveira","year":"2021","journal-title":"Curr. Opin. Virol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0320","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1264\/jsme2.ME14145","article-title":"Survival of enveloped and non-enveloped viruses on inanimate surfaces","volume":"30","author":"Firquet","year":"2015","journal-title":"Microbes Environ."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12985-022-01819-w","article-title":"Stability of enveloped and nonenveloped viruses in hydrolyzed gelatin liquid formulation","volume":"19","author":"Kadji","year":"2022","journal-title":"Virol. J."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0330","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s42254-020-00267-1","article-title":"Physics of viral dynamics","volume":"3","author":"Bruinsma","year":"2021","journal-title":"Nat. Rev. Phys."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb0335","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1021\/acssensors.7b00226","article-title":"Membrane fluidity sensing on the single virus particle level with Plasmonic nanoparticle transducers","volume":"2","author":"Feizpour","year":"2017","journal-title":"ACS Sens"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0340","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.90.11.5181","article-title":"Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes","volume":"90","author":"Aloia","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0345","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<76::AID-JPS8>3.0.CO;2-U","article-title":"Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies","volume":"89","author":"Evans","year":"2000","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0350","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","article-title":"Factors affecting stability of RNA - temperature, length, concentration, pH, and buffering species","volume":"113","author":"Chheda","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb0355","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1021\/acs.est.1c01255","article-title":"Duplex structure of double-stranded RNA provides stability against hydrolysis relative to single-stranded RNA","volume":"55","author":"Zhang","year":"2021","journal-title":"Environ. Sci. Technol."},{"issue":"5087","key":"10.1016\/j.addr.2025.115715_bb0360","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.1279808","article-title":"Stability and properties of double and triple helices: dramatic effects of RNA or DNA backbone composition","volume":"258","author":"Roberts","year":"1992","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0365","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1042\/BST20200854","article-title":"Lipid-protein interactions in virus assembly and budding from the host cell plasma membrane","volume":"49","author":"Motsa","year":"2021","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0370","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0375","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/bit.24493","article-title":"Vaccine process technology","volume":"109","author":"Josefsberg","year":"2012","journal-title":"Biotechnol. Bioeng."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb0380","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s11095-016-1979-0","article-title":"Is there an optimal formulation and delivery strategy for subunit vaccines?","volume":"33","author":"Bobbala","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2025.115715_bb0385","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-4615-0557-0_7","article-title":"Surfactant-protein interactions","volume":"13","author":"Randolph","year":"2002","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.addr.2025.115715_bb0390","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.ai.2021.08.003","article-title":"Antibody dependent enhancement: Unavoidable problems in vaccine development","volume":"151","author":"Xu","year":"2021","journal-title":"Adv. Immunol."},{"issue":"13","key":"10.1016\/j.addr.2025.115715_bb0395","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1021\/acs.est.6b05835","article-title":"Viral aggregation: impact on virus behavior in the environment","volume":"51","author":"Gerba","year":"2017","journal-title":"Environ. Sci. Technol."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12665\/J25.Croyle","article-title":"Role of the container\/closure system and formulation on agitation-induced aggregation phenomena in recombinant adenoviral products","volume":"2","author":"Croyle","year":"2003","journal-title":"Bioprocess. J."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0405","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ajic.2010.03.003","article-title":"Inactivation of influenza a virus H1N1 by disinfection process","volume":"38","author":"Jeong","year":"2010","journal-title":"Am. J. Infect. Control"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0410","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jviromet.2004.02.003","article-title":"Thermal inactivation of adenovirus type 5","volume":"118","author":"Maheshwari","year":"2004","journal-title":"J. Virol. Methods"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0415","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10867-018-9488-5","article-title":"Characterization of AAV vector particle stability at the single-capsid level","volume":"44","author":"Bernaud","year":"2018","journal-title":"J. Biol. Phys."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb0420","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"Evans","year":"2004","journal-title":"J. Pharm. Sci."},{"issue":"32","key":"10.1016\/j.addr.2025.115715_bb0425","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1016\/j.vaccine.2016.04.074","article-title":"Development of a stable liquid formulation of live attenuated influenza vaccine","volume":"34","author":"White","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/v11080725","article-title":"Forced degradation studies to identify critical process parameters for the purification of infectious measles virus","volume":"11","author":"Loewe","year":"2019","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0435","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1099\/0022-1317-10-3-209","article-title":"Some factors affecting the survival of airborne viruses","volume":"10","author":"Benbough","year":"1971","journal-title":"J. Gen. Virol."},{"issue":"14","key":"10.1016\/j.addr.2025.115715_bb0440","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1128\/JVI.03544-13","article-title":"Roles of humidity and temperature in shaping influenza seasonality","volume":"88","author":"Lowen","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2025.115715_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.138226","article-title":"Effects of temperature variation and humidity on the death of COVID-19 in Wuhan","volume":"724","author":"Ma","year":"2020","journal-title":"China. Sci Total Environ"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-3495(65)86715-7","article-title":"The physical state of viral nucleic acid and the sensitivity of viruses to ultraviolet light","volume":"5","author":"Rauth","year":"1965","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2025.115715_bb0460","first-page":"15","article-title":"The impact of capsid proteins on virus removal and inactivation during water treatment processes","volume":"8","author":"Mayer","year":"2015","journal-title":"Microbiol Insights"},{"key":"10.1016\/j.addr.2025.115715_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.watres.2021.117165","article-title":"Prediction of photolysis kinetics of viral genomes under UV(254) irradiation to estimate virus infectivity loss","volume":"198","author":"Cheng","year":"2021","journal-title":"Water Res."},{"issue":"14","key":"10.1016\/j.addr.2025.115715_bb0470","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1021\/es100435a","article-title":"Oxidation of virus proteins during UV(254) and singlet oxygen mediated inactivation","volume":"44","author":"Rule Wigginton","year":"2010","journal-title":"Environ. Sci. Technol."},{"issue":"22","key":"10.1016\/j.addr.2025.115715_bb0475","doi-asserted-by":"crossref","first-page":"14244","DOI":"10.1128\/JVI.79.22.14244-14252.2005","article-title":"Predicted inactivation of viruses of relevance to biodefense by solar radiation","volume":"79","author":"Lytle","year":"2005","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0480","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/15459620701329012","article-title":"Inactivation of viruses on surfaces by ultraviolet germicidal irradiation","volume":"4","author":"Tseng","year":"2007","journal-title":"J. Occup. Environ. Hyg."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0485","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cbic.201100601","article-title":"UV radiation induces genome-mediated, site-specific cleavage in viral proteins","volume":"13","author":"Wigginton","year":"2012","journal-title":"Chembiochem"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0490","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1128\/AEM.00663-13","article-title":"Subtle differences in virus composition affect disinfection kinetics and mechanisms","volume":"79","author":"Sigstam","year":"2013","journal-title":"Appl. Environ. Microbiol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0495","article-title":"Sanitizing agents for virus inactivation and disinfection","volume":"1","author":"Lin","year":"2020","journal-title":"View (Beijing)"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0500","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jhin.2017.08.025","article-title":"Efficacy of ethanol against viruses in hand disinfection","volume":"98","author":"Kampf","year":"2018","journal-title":"J. Hosp. Infect."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0505","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/am.21.4.606-610.1971","article-title":"Inactivation of influenza and other viruses by a mixture of virucidal compounds","volume":"21","author":"Oxford","year":"1971","journal-title":"Appl. Microbiol."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0510","first-page":"803","article-title":"Effects of electrolytes on virus inactivation by acidic solutions","volume":"27","author":"Nishide","year":"2011","journal-title":"Int. J. Mol. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jps.20496","article-title":"Effect of pH and ionic strength on the physical stability of adenovirus type 5","volume":"95","author":"Rexroad","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.addr.2025.115715_bb0520","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.gt.3301527","article-title":"Development of formulations that enhance physical stability of viral vectors for gene therapy","volume":"8","author":"Croyle","year":"2001","journal-title":"Gene Ther."},{"issue":"19","key":"10.1016\/j.addr.2025.115715_bb0525","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1128\/JVI.05291-11","article-title":"Low-pH-dependent changes in the conformation and oligomeric state of the prefusion form of herpes simplex virus glycoprotein B are separable from fusion activity","volume":"85","author":"Dollery","year":"2011","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.addr.2025.115715_bb0530","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00839-18","article-title":"Bovine herpesvirus 1 entry by a low-pH endosomal pathway","volume":"92","author":"Pastenkos","year":"2018","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.addr.2025.115715_bb0535","doi-asserted-by":"crossref","first-page":"17436","DOI":"10.1021\/acsnano.3c05508","article-title":"Human immunodeficiency virus 1 preferentially fuses with pH-neutral endocytic vesicles in cell lines and human primary CD4+ T-cells","volume":"17","author":"Sharma","year":"2023","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0540","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01749-18","article-title":"Histidine-rich glycoprotein inhibits HIV-1 infection in a pH-dependent manner","volume":"93","author":"Dantas","year":"2019","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb0545","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.tim.2018.03.005","article-title":"Influenza hemagglutinin protein stability, activation, and pandemic risk","volume":"26","author":"Russell","year":"2018","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0450","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/14760584.2023.2273901","article-title":"Challenges in vaccine transport: can we deliver without the cold chain?","volume":"22","author":"Bajrovic","year":"2023","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0550","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4068\/cmj.2025.61.1.19","article-title":"Biopharmaceutical analysis by HPLC: practices and challenges","volume":"61","author":"Mahdi","year":"2025","journal-title":"Chonnam Med. J."},{"key":"10.1016\/j.addr.2025.115715_bb0555","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jchromb.2016.04.001","article-title":"Challenges and opportunities of using liquid chromatography and mass spectrometry methods to develop complex vaccine antigens as pharmaceutical dosage forms","volume":"1032","author":"Hickey","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb0560","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.vaccine.2015.01.031","article-title":"Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens","volume":"33","author":"Yang","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb0565","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.xphs.2020.09.011","article-title":"Preservation of quaternary structure in thermostable, lyophilized filovirus glycoprotein vaccines: a search for stability-indicating assays","volume":"109","author":"Preston","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"9\u201310","key":"10.1016\/j.addr.2025.115715_bb0570","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/elps.202100269","article-title":"Sixteen capillary electrophoresis applications for viral vaccine analysis","volume":"43","author":"Geurink","year":"2022","journal-title":"Electrophoresis"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0575","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/EBC20220101","article-title":"Charge detection mass spectrometry for the analysis of viruses and virus-like particles","volume":"67","author":"Miller","year":"2023","journal-title":"Essays Biochem."},{"issue":"35","key":"10.1016\/j.addr.2025.115715_bb0580","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1021\/acs.analchem.1c01893","article-title":"Characterization of classical vaccines by charge detection mass spectrometry","volume":"93","author":"Miller","year":"2021","journal-title":"Anal. Chem."},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115715_bb0585","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/mas.21571","article-title":"The expanding role of mass spectrometry in the field of vaccine development","volume":"39","author":"Sharma","year":"2020","journal-title":"Mass Spectrom. Rev."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0590","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/jps.22282","article-title":"Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines","volume":"100","author":"Ausar","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"21","key":"10.1016\/j.addr.2025.115715_bb0595","doi-asserted-by":"crossref","first-page":"13794","DOI":"10.1021\/acs.analchem.9b03259","article-title":"Automated high-throughput capillary circular dichroism and intrinsic fluorescence spectroscopy for rapid determination of protein structure","volume":"91","author":"Moore-Kelly","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2025.115715_bb0600","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ejpb.2021.05.013","article-title":"Application of ultraviolet, visible, and infrared light imaging in protein-based biopharmaceutical formulation characterization and development studies","volume":"165","author":"Klijn","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031764","article-title":"Fluorescence-based protein stability monitoring-a review","volume":"25","author":"Gooran","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb0610","series-title":"Chapter 3 - Structural analysis of biomacromolecules using circular dichroism spectroscopy, in Advanced Spectroscopic Methods to Study Biomolecular Structure and Dynamics","first-page":"77","author":"Zhao","year":"2023"},{"key":"10.1016\/j.addr.2025.115715_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114945","article-title":"Circular dichroism of biopharmaceutical proteins in a quality-regulated environment","volume":"219","author":"Jones","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"28","key":"10.1016\/j.addr.2025.115715_bb0620","doi-asserted-by":"crossref","first-page":"19478","DOI":"10.1074\/jbc.M603313200","article-title":"Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature","volume":"281","author":"Ausar","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0625","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/mp0500465","article-title":"Analysis of the thermal and pH stability of human respiratory syncytial virus","volume":"2","author":"Ausar","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb0630","series-title":"Chapter 11 - Differential scanning calorimetry in the biopharmaceutical sciences, in Biophysical Characterization of Proteins in Developing Biopharmaceuticals (Second Edition)","first-page":"311","author":"Demarest","year":"2020"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0635","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/A:1010162429900","article-title":"Use of isothermal titration calorimetry in the development of molecularly defined vaccines","volume":"57","author":"Pluschke","year":"1999","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.addr.2025.115715_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123063","article-title":"Isothermal titration calorimetry (ITC) as a promising tool in pharmaceutical nanotechnology","volume":"641","author":"Lima Cavalcanti","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb0645","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2154100","article-title":"Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication","volume":"18","author":"Kumar","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0650","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.xphs.2020.11.039","article-title":"Rapid Developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: case-study with non-replicating rotavirus (NRRV) vaccine antigens","volume":"110","author":"Sawant","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb0655","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2021.11.012","article-title":"Evaluation of intermolecular interactions required for thermostability of a recombinant adenovirus within a film matrix","volume":"341","author":"Bajrovic","year":"2022","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111112","article-title":"Particle detection and characterization for biopharmaceutical applications: current principles of established and alternative techniques","volume":"12","author":"Gross-Rother","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0665","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.xphs.2021.12.011","article-title":"Particles in biopharmaceutical formulations, part 2: An update on analytical techniques and applications for therapeutic proteins, viruses","volume":"111","author":"Roesch","year":"2022","journal-title":"Vaccines and Cells. J Pharm Sci"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0670","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11095-024-03698-y","article-title":"Assessment of tunable resistive pulse sensing (TRPS) Technology for Particle Size Distribution in vaccine formulations - a comparative study with dynamic light scattering","volume":"41","author":"Misra","year":"2024","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0675","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/bio-2017-0176","article-title":"Principles of vaccine potency assays","volume":"10","author":"Verch","year":"2018","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0680","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41541-022-00470-4","article-title":"Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies","volume":"7","author":"Sanyal","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0685","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/14760584.2023.2178421","article-title":"Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays","volume":"22","author":"Zhang","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2025.115715_bb0690","unstructured":"Biophysical Characterization of Proteins in Developing Biopharmaceuticals, ed. S.A.B. Damian J. Houde. 2019."},{"key":"10.1016\/j.addr.2025.115715_bb0695","series-title":"Pharmaceutical Biotechnology: Fundamentals and Applications","first-page":"33","article-title":"Protein stability and characterization","author":"Koulov","year":"2019"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0700","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.xphs.2019.10.026","article-title":"A comparison between emerging and current biophysical methods for the assessment of higher-order structure of biopharmaceuticals","volume":"109","author":"Wen","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"24","key":"10.1016\/j.addr.2025.115715_bb0705","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.4155\/bio-2021-0096","article-title":"Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective","volume":"13","author":"Baldwin","year":"2021","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0710","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-021-00317-4","article-title":"Considerations for bioanalytical characterization and batch release of COVID-19 vaccines","volume":"6","author":"Sanyal","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0715","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41541-023-00692-0","article-title":"Availability and use of standards in vaccine development","volume":"8","author":"Avumegah","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0720","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbapap.2004.08.007","article-title":"The oxidative environment and protein damage","volume":"1703","author":"Davies","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0725","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1520-6017(200103)90:3<253::AID-JPS1>3.0.CO;2-W","article-title":"Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition","volume":"90","author":"Hovorka","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0730","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","article-title":"Stability of protein pharmaceuticals: an update","volume":"27","author":"Manning","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2025.115715_bb0735","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jchromb.2016.04.037","article-title":"Challenges in liquid chromatographic characterization of proteins","volume":"1032","author":"Bob\u00e1ly","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"6110","key":"10.1016\/j.addr.2025.115715_bb0740","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.1219021","article-title":"The protein-folding problem, 50 years on","volume":"338","author":"Dill","year":"2012","journal-title":"Science"},{"issue":"Pt 1","key":"10.1016\/j.addr.2025.115715_bb0745","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijbiomac.2017.07.116","article-title":"A review on protein misfolding, aggregation and strategies to prevent related ailments","volume":"105","author":"Shamsi","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"issue":"13","key":"10.1016\/j.addr.2025.115715_bb0750","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.addr.2011.06.011","article-title":"Interactions of formulation excipients with proteins in solution and in the dried state","volume":"63","author":"Ohtake","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb0755","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/jps.22597","article-title":"Effects of surfaces and leachables on the stability of biopharmaceuticals","volume":"100","author":"Bee","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"42","key":"10.1016\/j.addr.2025.115715_bb0760","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1016\/j.vaccine.2015.08.085","article-title":"Freeze-drying of live virus vaccines: a review","volume":"33","author":"Hansen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118505","article-title":"Science and art of protein formulation development","volume":"568","author":"Wang","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0770","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/21645515.2018.1526585","article-title":"Osmolytes in vaccine production, flocculation and storage: a critical review","volume":"15","author":"Hasan","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"issue":"37","key":"10.1016\/j.addr.2025.115715_bb0775","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1021\/acs.jpcb.7b05541","article-title":"Stability of proteins in carbohydrates and other additives during freezing: the human growth hormone as a case study","volume":"121","author":"Arsiccio","year":"2017","journal-title":"J. Phys. Chem. B"},{"issue":"37","key":"10.1016\/j.addr.2025.115715_bb0780","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1021\/acs.jpcb.8b06572","article-title":"Sugar-mediated stabilization of protein against chemical or thermal denaturation","volume":"122","author":"Ajito","year":"2018","journal-title":"J. Phys. Chem. B"},{"issue":"22","key":"10.1016\/j.addr.2025.115715_bb0785","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1046\/j.1432-1033.2003.03850.x","article-title":"Prevention of thermal inactivation and aggregation of lysozyme by polyamines","volume":"270","author":"Kudou","year":"2003","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb0790","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11095-018-2398-1","article-title":"Improving viscosity and stability of a highly concentrated monoclonal antibody solution with concentrated proline","volume":"35","author":"Hung","year":"2018","journal-title":"Pharm. Res."},{"issue":"30","key":"10.1016\/j.addr.2025.115715_bb0795","doi-asserted-by":"crossref","first-page":"9270","DOI":"10.1073\/pnas.1511780112","article-title":"How osmolytes influence hydrophobic polymer conformations: a unified view from experiment and theory","volume":"112","author":"Mondal","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.addr.2025.115715_bb0800","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1016\/S0021-9258(19)68947-7","article-title":"The stabilization of proteins by sucrose","volume":"256","author":"Lee","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0805","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/polym3041972","article-title":"Water soluble polymers for pharmaceutical applications","volume":"3","author":"Kadajji","year":"2011","journal-title":"Polymers"},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb0810","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/pharmaceutics14122575","article-title":"Alternative excipients for protein stabilization in protein therapeutics: overcoming the limitations of Polysorbates","volume":"14","author":"Casta\u00f1eda Ruiz","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0815","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ddr.21452","article-title":"Cyclodextrin complexes: perspective from drug delivery and formulation","volume":"79","author":"Jacob","year":"2018","journal-title":"Drug Dev. Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0820","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.xphs.2021.12.002","article-title":"Emerging challenges and innovations in surfactant-mediated stabilization of biologic formulations","volume":"111","author":"Katz","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2021.03.003","article-title":"Stabilizers and their interaction with formulation components in frozen and freeze-dried protein formulations","volume":"173","author":"Thakral","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Pt A","key":"10.1016\/j.addr.2025.115715_bb0830","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejpb.2015.09.016","article-title":"Key interactions of surfactants in therapeutic protein formulations: a review","volume":"97","author":"Khan","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115715_bb0835","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2016.09.003","article-title":"Arginine as a protein stabilizer and destabilizer in liquid formulations","volume":"513","author":"Kim","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0840","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2174\/138920371506140818113015","article-title":"Multi-faceted arginine: mechanism of the effects of arginine on protein","volume":"15","author":"Arakawa","year":"2014","journal-title":"Curr. Protein Pept. Sci."},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb0845","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1021\/bi047528r","article-title":"Role of arginine in the stabilization of proteins against aggregation","volume":"44","author":"Baynes","year":"2005","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115715_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2006.12.007","article-title":"Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects","volume":"127","author":"Arakawa","year":"2007","journal-title":"Biophys. Chem."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0855","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12985-017-0897-z","article-title":"The pH stability of foot-and-mouth disease virus","volume":"14","author":"Yuan","year":"2017","journal-title":"Virol. J."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0860","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10040-017-1559-3","article-title":"The effects of ionic strength and organic matter on virus inactivation at low temperatures: general likelihood uncertainty estimation (GLUE) as an alternative to least-squares parameter optimization for the fitting of virus inactivation models","volume":"25","author":"Mayotte","year":"2017","journal-title":"Hydrogeol. J."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0865","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/jps.24429","article-title":"Protein adsorption, desorption, and aggregation mediated by solid-liquid interfaces","volume":"104","author":"Perevozchikova","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0870","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1039\/C3SM51994E","article-title":"Both protein adsorption and aggregation contribute to shear yielding and viscosity increase in protein solutions","volume":"10","author":"Castellanos","year":"2014","journal-title":"Soft Matter"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb0875","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00467-022-05668-1","article-title":"Serum osmolality and hyperosmolar states","volume":"38","author":"B\u00fcy\u00fckkarag\u00f6z","year":"2023","journal-title":"Pediatr. Nephrol."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0880","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/bm0344957","article-title":"Effect of surfactant type on surfactant--protein interactions at the air-water interface","volume":"5","author":"Gunning","year":"2004","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0885","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/jfb3030528","article-title":"Surface treatment of polymeric materials controlling the adhesion of biomolecules","volume":"3","author":"Poncin-Epaillard","year":"2012","journal-title":"J Funct Biomater"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0890","doi-asserted-by":"crossref","DOI":"10.1116\/1.5045122","article-title":"Practical guide to characterize biomolecule adsorption on solid surfaces (review)","volume":"13","author":"Migliorini","year":"2018","journal-title":"Biointerphases"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb0895","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1021\/bm500762u","article-title":"Electrostatic stabilization of \u03b2-lactoglobulin fibrils at increased pH with cationic polymers","volume":"15","author":"Gilbert","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2025.115715_bb0900","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfa.2018.08.042","article-title":"Stabilization of electrostatic polymer-colloid complexes","volume":"558","author":"Yaroslavov","year":"2018","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb1020","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/prot.22786","article-title":"On the pH-optimum of activity and stability of proteins","volume":"78","author":"Talley","year":"2010","journal-title":"Proteins"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpb.2013.05.019","article-title":"Recent advances and further challenges in lyophilization","volume":"85","author":"Kasper","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2025.115715_bb1030","series-title":"Vaccine Development and Manufacturing","first-page":"263","article-title":"Lyophilization in vaccine processes","author":"Wasserman","year":"2015"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/bit.260370210","article-title":"Moisture-induced aggregation of lyophilized proteins in the solid state","volume":"37","author":"Liu","year":"1991","journal-title":"Biotechnol. Bioeng."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb0915","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/jps.21825","article-title":"Mechanisms of protein stabilization in the solid state","volume":"98","author":"Chang","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1081\/PDT-100101354","article-title":"Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems","volume":"4","author":"Mattern","year":"1999","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1045","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.xphs.2017.11.015","article-title":"Arginine as an excipient for protein freeze-drying: a Mini review","volume":"107","author":"St\u00e4rtzel","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb0905","doi-asserted-by":"crossref","DOI":"10.1063\/1.4944680","article-title":"Effects of monohydric alcohols and polyols on the thermal stability of a protein","volume":"144","author":"Murakami","year":"2016","journal-title":"J. Chem. Phys."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0910","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1023\/A:1015825027737","article-title":"Protein--solvent interactions in pharmaceutical formulations","volume":"8","author":"Arakawa","year":"1991","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb0920","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13104-018-3362-1","article-title":"Assessment of temperatures in the vaccine cold chain in two provinces in Lao People\u2019s Democratic Republic: a cross-sectional pilot study","volume":"11","author":"Kitamura","year":"2018","journal-title":"BMC. Res. Notes"},{"issue":"17","key":"10.1016\/j.addr.2025.115715_bb0925","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.vaccine.2016.09.070","article-title":"Is freezing in the vaccine cold chain an ongoing issue? A literature review","volume":"35","author":"Hanson","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb0930","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1017\/dmp.2016.195","article-title":"Earthquakes, fuel crisis, power outages, and health Care in Nepal: implications for the future","volume":"11","author":"Adhikari","year":"2017","journal-title":"Disaster Med. Public Health Prep."},{"key":"10.1016\/j.addr.2025.115715_bb0935","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13104-015-1257-y","article-title":"Factors associated with the exposure of vaccines to adverse temperature conditions: the case of north west region","volume":"8","author":"Yakum","year":"2015","journal-title":"Cameroon. BMC Res Notes"},{"issue":"33","key":"10.1016\/j.addr.2025.115715_bb0940","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1016\/j.vaccine.2020.06.014","article-title":"A vaccine cold chain temperature monitoring study in the united Mexican states","volume":"38","author":"Falc\u00f3n","year":"2020","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.addr.2025.115715_bb0945","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.vaccine.2016.08.045","article-title":"Improving cold chain systems: challenges and solutions","volume":"35","author":"Ashok","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0950","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.vaccine.2017.10.059","article-title":"Turning up the heat: effect of new vaccine for children\u2019s (VFC) program recommendations for use of temperature monitors upon incorrect product storage adverse event reporting","volume":"36","author":"Wilson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb0955","series-title":"Temperature Monitoring Study: a Fully Documented Process to Detect Weaknesses in the Supply Chain: evidence Brief","author":"World Health","year":"2018"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb0960","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bbamem.2010.07.035","article-title":"Ice-induced partial unfolding and aggregation of an integral membrane protein","volume":"1798","author":"Garber Cohen","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb0965","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0009922817728702","article-title":"Recurrent sterile abscesses after immunization with aluminum-adjuvant based vaccines","volume":"57","author":"Vargas","year":"2018","journal-title":"Clin. Pediatr. (Phila)"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb0970","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2471\/BLT.08.056879","article-title":"Validation of the shake test for detecting freeze damage to adsorbed vaccines","volume":"88","author":"Kartoglu","year":"2010","journal-title":"Bull. World Health Organ."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb0975","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0011-2240(88)90032-6","article-title":"The mechanism of cryoprotection of proteins by solutes","volume":"25","author":"Carpenter","year":"1988","journal-title":"Cryobiology"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb0980","doi-asserted-by":"crossref","DOI":"10.3390\/biom9080347","article-title":"The impact of salts on the ice recrystallization inhibition activity of antifreeze (Glyco)proteins","volume":"9","author":"Sur\u00eds-Valls","year":"2019","journal-title":"Biomolecules"},{"issue":"24","key":"10.1016\/j.addr.2025.115715_bb0985","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1021\/jacs.8b03903","article-title":"Osmolytes and protein-protein interactions","volume":"140","author":"Rydeen","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2025.115715_bb0990","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/206115b0","article-title":"FREEZE-DRYING OF CERTAIN VIRUSES","volume":"206","author":"Tyrrell","year":"1965","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb0995","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-3059.1960.tb01150.x","article-title":"PRESERVATION OF SOME PLANT VIRUSES BY FREEZE-DRYING","volume":"9","author":"Hollings","year":"1960","journal-title":"Plant Pathol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1000","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3181\/00379727-86-21081","article-title":"Lyophilization of poliomyelitis virus; heat inactivation of dry MEFl virus","volume":"86","author":"Kraft","year":"1954","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.addr.2025.115715_bb1005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2021.01.016","article-title":"Stability of lyophilized and spray dried vaccine formulations","volume":"171","author":"Preston","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115715_bb1010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-981-13-1244-1_20","article-title":"Applications of freezing and freeze-drying in pharmaceutical formulations","volume":"1081","author":"Izutsu","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40005-022-00610-x","article-title":"Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals","volume":"53","author":"Emami","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.addr.2025.115715_bb1050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-4615-0549-5_6","article-title":"Fundamentals of freeze-drying","volume":"14","author":"Nail","year":"2002","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.addr.2025.115715_bb1055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/B978-0-12-407672-3.00002-2","article-title":"Fungal spores for dispersion in space and time","volume":"85","author":"Wyatt","year":"2013","journal-title":"Adv. Appl. Microbiol."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb1060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1360-1385(01)02052-0","article-title":"Mechanisms of plant desiccation tolerance","volume":"6","author":"Hoekstra","year":"2001","journal-title":"Trends Plant Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/B:PHAM.0000016234.73023.75","article-title":"Design of freeze-drying processes for pharmaceuticals: practical advice","volume":"21","author":"Tang","year":"2004","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1085","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s11095-023-03607-9","article-title":"Practical advice on scientific Design of Freeze-Drying Process: 2023 update","volume":"40","author":"Tchessalov","year":"2023","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1208\/s12249-009-9362-7","article-title":"Determination of end point of primary drying in freeze-drying process control","volume":"11","author":"Patel","year":"2010","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1208\/s12249-011-9600-7","article-title":"Optimization of the secondary drying step in freeze drying using TDLAS technology","volume":"12","author":"Schneid","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2025.115715_bb1095","first-page":"76","article-title":"A Review on Freeze Drying Process of Pharmaceuticals","author":"Khairnar","year":"2013","journal-title":"International Journal of Research in Pharmacy and science"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/03639040802192806","article-title":"Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation","volume":"35","author":"Lang","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0092-1157(82)80026-7","article-title":"Determination of residual moisture in freeze-dried viral vaccines: Karl Fischer gravimetric and thermogravimetric methodologies","volume":"10","author":"May","year":"1982","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.addr.2025.115715_bb1100","series-title":"WHO Guidance Note: Vaccine Diluents. The Proper Use and Handling of Vaccine Diluents","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.addr.2025.115715_bb1105","unstructured":"Immunization Action Coalition. 12\/2022 Vaccines with diluents: how to use them. Information Sheet www.immunize.org\/catg.d\/p3040.pdf (accessed 10\/06\/25)."},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb1110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164692","article-title":"Development of a freeze-dried, heat-stable influenza subunit vaccine formulation","volume":"11","author":"Flood","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jamp.2021.0056","article-title":"Spray drying and particle engineering in dosage form Design for Global Vaccines","volume":"35","author":"Gomez","year":"2022","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1120","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1080\/21645515.2017.1356952","article-title":"Developments in the formulation and delivery of spray dried vaccines","volume":"13","author":"Kanojia","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2025.115715_bb1125","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2018.10.026","article-title":"Spray drying of pharmaceuticals and biopharmaceuticals: critical parameters and experimental process optimization approaches","volume":"127","author":"Ziaee","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125422","article-title":"The value of spray drying as stabilization process for proteins","volume":"674","author":"Kopp","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb1135","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.foodhyd.2019.03.023","article-title":"The role of viscosity in morphology development during single droplet drying","volume":"94","author":"Both","year":"2019","journal-title":"Food Hydrocoll."},{"issue":"Pt 2","key":"10.1016\/j.addr.2025.115715_bb1140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BA20030133","article-title":"Freeze-drying of proteins: some emerging concerns","volume":"39","author":"Roy","year":"2004","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.addr.2025.115715_bb1145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2018.07.035","article-title":"Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization","volume":"286","author":"Kanojia","year":"2018","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jamp.2014.1176","article-title":"Spray-dried influenza antigen with Trehalose and leucine produces an Aerosolizable powder vaccine formulation that induces strong systemic and mucosal immunity after pulmonary administration","volume":"28","author":"Sou","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2025.115715_bb1155","series-title":"Spray Drying of Biopharmaceuticals: Stability and Process Considerations","first-page":"763","volume":"vol. 24","author":"Ameri","year":"2006"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable dry powder formulation for nasal delivery of anthrax vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ijpharm.2016.08.022","article-title":"A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine","volume":"511","author":"Kanojia","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1170","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.vaccine.2009.11.024","article-title":"Heat-stable measles vaccine produced by spray drying","volume":"28","author":"Ohtake","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb1175","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s11095-016-2003-4","article-title":"Optimization of spray drying conditions for yield, particle size and biological activity of thermally stable viral vectors","volume":"33","author":"LeClair","year":"2016","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2010.02.025","article-title":"A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation","volume":"144","author":"Saluja","year":"2010","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jps.10294","article-title":"Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application","volume":"92","author":"Maa","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb1190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2014.01.005","article-title":"Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars","volume":"55","author":"Tonnis","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1195","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1128\/CVI.00447-08","article-title":"Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine","volume":"16","author":"Huang","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1200","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/jps.1032","article-title":"Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization","volume":"90","author":"Sellers","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/jamp.2007.0658","article-title":"Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine","volume":"21","author":"Burger","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb1210","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s11095-008-9575-6","article-title":"Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids","volume":"25","author":"Cape","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2025.115715_bb1215","series-title":"United States Pharmacopeial Convention, Pharmaceutical Dosage Forms in USP35 NF30, 2012: U. S. Pharmacopoeia National Formulary","first-page":"765","volume":"vol. 35","year":"2012"},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb1220","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1517\/17425247.2013.804058","article-title":"Oromucosal film preparations: classification and characterization methods","volume":"10","author":"Preis","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2025.115715_bb1225","series-title":"Specialized Pharmaceutical Formulation: The Science and Technology of Dosage Forms","first-page":"151","article-title":"Oral Films","author":"Whiteman","year":"2022"},{"key":"10.1016\/j.addr.2025.115715_bb1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120759","article-title":"Recent advances of oral film as platform for drug delivery","volume":"604","author":"He","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1235","first-page":"111","article-title":"Current overview of Oral thin films. Turk","volume":"18","author":"Sevin\u00e7 \u00d6zakar","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb1240","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jconrel.2022.10.059","article-title":"Oromucosal delivery of macromolecules: challenges and recent developments to improve bioavailability","volume":"352","author":"Rawas-Qalaji","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1245","first-page":"53","article-title":"Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties","volume":"2","author":"Peh","year":"1999","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.addr.2025.115715_bb1250","doi-asserted-by":"crossref","DOI":"10.3390\/ma14174872","article-title":"\u201csuccess depends on your backbone\u201d-about the use of polymers as essential materials forming Orodispersible films","volume":"14","author":"Olechno","year":"2021","journal-title":"Materials (Basel)"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1255","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijpharm.2015.08.038","article-title":"Mucoadhesive oral films: the potential for unmet needs","volume":"494","author":"Silva","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12249-016-0525-z","article-title":"Overview and future potential of buccal Mucoadhesive films as drug delivery Systems for Biologics","volume":"18","author":"Montenegro-Nicolini","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1265","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","article-title":"Strategies to improve micelle stability for drug delivery","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res"},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1270","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau4819","article-title":"Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature","volume":"6","author":"Bajrovic","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/03639040903117348","article-title":"Critical evaluation of permeation enhancers for oral mucosal drug delivery","volume":"36","author":"Sohi","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb1280","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.3390\/molecules200814451","article-title":"Absorption-enhancing effects of bile salts","volume":"20","author":"Moghimipour","year":"2015","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1285","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2221-1691(13)60060-X","article-title":"Bioavailability enhancers of herbal origin: an overview","volume":"3","author":"Kesarwani","year":"2013","journal-title":"Asian Pac. J. Trop. Biomed."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejpb.2010.11.023","article-title":"Manufacture and characterization of mucoadhesive buccal films","volume":"77","author":"Morales","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1295","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1018906330308","article-title":"Alveolar permeability enhancement by oleic acid and related fatty acids: evidence for a calcium-dependent mechanism","volume":"11","author":"Wang","year":"1994","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115715_bb1300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2011.04.011","article-title":"Modulation of the thermodynamic stability of proteins by polyols: significance of polyol hydrophobicity and impact on the chemical potential of water","volume":"413","author":"Kumar","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijpharm.2012.12.027","article-title":"Mechanisms of polymeric film formation","volume":"457","author":"Felton","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb1310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfoodeng.2019.109809","article-title":"Effects of plasticizers on water sorption and aging stability of whey protein\/carboxy methyl cellulose films","author":"Huntrakul","year":"2020","journal-title":"J. Food Eng."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1315","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1038\/s41598-019-44020-w","article-title":"Thermal stabilization of viral vaccines in low-cost sugar films","volume":"9","author":"Leung","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb1320","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.vaccine.2019.12.062","article-title":"Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine","volume":"38","author":"Stinson","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13346-016-0282-2","article-title":"Long-term stability of influenza vaccine in a dissolving microneedle patch","volume":"7","author":"Mistilis","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1330","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2009.10.013","article-title":"Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity","volume":"142","author":"Kim","year":"2010","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb1335","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1021\/acs.langmuir.5c00443","article-title":"Influence of bulk viscosity on the interfacial properties of highly viscous extended liquid thin films","volume":"41","author":"Biswas","year":"2025","journal-title":"Langmuir"},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb1340","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/pharmaceutics15122753","article-title":"Orodispersible films: current innovations and emerging trends","volume":"15","author":"Jacob","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb1345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/00220345231164111","article-title":"Mucoadhesive vaccine delivery systems for the oral mucosa","volume":"102","author":"Mokabari","year":"2023","journal-title":"J. Dent. Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1350","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s43856-022-00212-6","article-title":"Thermostability and in vivo performance of AAV9 in a film matrix","volume":"2","author":"Doan","year":"2022","journal-title":"Commun. Med. (Lond)."},{"key":"10.1016\/j.addr.2025.115715_bb1355","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejpb.2023.08.005","article-title":"Physical characteristics and stability profile of recombinant plasmid DNA within a film matrix","volume":"190","author":"Doan","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102179","article-title":"Identification of film-based formulations that move mRNA lipid nanoparticles out of the freezer","volume":"35","author":"Doan","year":"2024","journal-title":"Mol. Ther Nucleic Acids"},{"issue":"7271","key":"10.1016\/j.addr.2025.115715_bb1365","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/bmj.321.7271.1237","article-title":"The importance of injecting vaccines into muscle. Different patients need different needle sizes","volume":"321","author":"Zuckerman","year":"2000","journal-title":"Bmj"},{"key":"10.1016\/j.addr.2025.115715_bb1370","series-title":"Clinical Skills and Nursing Techniques","first-page":"538","article-title":"Parenteral medications","author":"Perry","year":"2014"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1375","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2025.115715_bb1380","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/491316","article-title":"Aluminum-induced entropy in biological systems: implications for neurological disease","volume":"2014","author":"Shaw","year":"2014","journal-title":"J. Toxicol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1385","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00144763","article-title":"Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study","volume":"4","author":"de Lalla","year":"1988","journal-title":"Eur. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1390","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0264-410X(89)90157-6","article-title":"Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination","volume":"7","author":"Shaw","year":"1989","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb1395","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2025.115715_bb1400","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1741-7015-7-16","article-title":"Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial","volume":"7","author":"Gillet","year":"2009","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1405","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1086\/317553","article-title":"Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous","volume":"32","author":"Ruben","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb1410","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/0264-410X(96)00044-8","article-title":"Immunogenicity and safety of a new inactivated hepatitis a vaccine: a clinical trial with comparison of administration route","volume":"14","author":"Fisch","year":"1996","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1415","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.intimp.2013.12.023","article-title":"Are the anatomical sites for vaccine administration selected judiciously?","volume":"19","author":"Malik","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb1420","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/jid.2008.56","article-title":"\u201cdermal dendritic cells\u201d comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages","volume":"128","author":"Ochoa","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.addr.2025.115715_bb1425","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jconrel.2016.02.014","article-title":"Mucosal vaccine delivery: current state and a pediatric perspective","volume":"240","author":"Shakya","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1430","first-page":"146","article-title":"The skin as an immune organ","volume":"160","author":"Salmon","year":"1994","journal-title":"West. J. Med."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1435","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2018.12.016","article-title":"Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID\u2122","volume":"37","author":"Van Mulder","year":"2019","journal-title":"Vaccine"},{"issue":"9944","key":"10.1016\/j.addr.2025.115715_bb1440","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0140-6736(14)60524-9","article-title":"Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial","volume":"384","author":"McAllister","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1445","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4161\/hv.24702","article-title":"Tolerability of intramuscular and intradermal delivery by CELLECTRA(\u00ae) adaptive constant current electroporation device in healthy volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1450","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425247.2016.1121990","article-title":"Clinical potential of electroporation for gene therapy and DNA vaccine delivery","volume":"13","author":"Lambricht","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1455","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/pharmaceutics7040438","article-title":"Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum","volume":"7","author":"Alkilani","year":"2015","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1460","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/tde-2017-0032","article-title":"Microneedles for vaccine delivery: challenges and future perspectives","volume":"8","author":"Shin","year":"2017","journal-title":"Ther. Deliv."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1465","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2012.07.039","article-title":"Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations","volume":"162","author":"Pattani","year":"2012","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1470","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/CVI.00435-10","article-title":"Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity","volume":"18","author":"Weldon","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb1475","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2017.02.011","article-title":"Microneedle, bio-microneedle and bio-inspired microneedle: a review","volume":"251","author":"Ma","year":"2017","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1480","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0167-5699(92)90158-4","article-title":"The role of nasopharyngeal lymphoid tissue","volume":"13","author":"Kuper","year":"1992","journal-title":"Immunol. Today"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1485","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/21645515.2016.1239668","article-title":"Current prospects and future challenges for nasal vaccine delivery","volume":"13","author":"Yusuf","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115715_bb1490","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(01)00149-1","article-title":"Exploiting M cells for drug and vaccine delivery","volume":"50","author":"Clark","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1495","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/21645515.2017.1377376","article-title":"Immune responses after live attenuated influenza vaccination","volume":"14","author":"Mohn","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb1500","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/14760584.2018.1541407","article-title":"Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine","volume":"17","author":"Korenkov","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2025.115715_bb1505","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/jpids\/piz083","article-title":"Understanding immunity in children vaccinated with live attenuated influenza vaccine","volume":"9","author":"Shannon","year":"2020","journal-title":"J. Pediatric Infect Dis. Soc."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2025.115715_bb1510","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2011.04.119","article-title":"A pandemic influenza vaccine in India: from strain to sale within 12 months","volume":"29","author":"Dhere","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb1515","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3389\/fimmu.2019.01605","article-title":"Innovative mucosal vaccine formulations against influenza a virus infections","volume":"10","author":"Calzas","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13346-012-0089-8","article-title":"CriticalSorb\u2122: enabling systemic delivery of macromolecules via the nasal route","volume":"3","author":"Lewis","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1525","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/head.13737","article-title":"A phase 1, randomized, open-label, safety, tolerability, and comparative bioavailability study of intranasal Dihydroergotamine powder (STS101), intramuscular Dihydroergotamine Mesylate, and intranasal DHE Mesylate spray in healthy adult subjects","volume":"60","author":"Albrecht","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.addr.2025.115715_bb1530","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2019.11.006","article-title":"Chitosan oral patches inspired by mussel adhesion","volume":"317","author":"Ryu","year":"2020","journal-title":"J. Control. Release"},{"issue":"24","key":"10.1016\/j.addr.2025.115715_bb1535","doi-asserted-by":"crossref","DOI":"10.3390\/polym14245459","article-title":"Bio-inspired Muco-adhesive polymers for drug delivery applications","volume":"14","author":"Jawadi","year":"2022","journal-title":"Polymers (Basel)"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1540","doi-asserted-by":"crossref","DOI":"10.3390\/md20050335","article-title":"Multiple roles of chitosan in mucosal drug delivery: An updated review","volume":"20","author":"Mura","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.addr.2025.115715_bb1545","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/112_2021_69","article-title":"A review: uses of chitosan in pharmaceutical forms","volume":"184","author":"Fren\u021b","year":"2023","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2025.115715_bb1550","doi-asserted-by":"crossref","unstructured":"Watts, P., A. Smith, and M. Hinchcliffe, ChiSys\u00ae as a Chitosan-Based Delivery Platform for Nasal Vaccination, in Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies, J. das Neves and B. Sarmento, Editors. 2014, Springer US: Boston, MA. p. 499\u2013516.","DOI":"10.1007\/978-1-4614-9524-6_23"},{"key":"10.1016\/j.addr.2025.115715_bb1555","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","article-title":"Chitosan in nasal delivery systems for therapeutic drugs","volume":"190","author":"Casettari","year":"2014","journal-title":"J. Control. Release"},{"issue":"1\u20131","key":"10.1016\/j.addr.2025.115715_bb1560","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/pr.2017.239","article-title":"Perspectives from the Society for Pediatric Research: decreased effectiveness of the live attenuated influenza vaccine","volume":"83","author":"Gill","year":"2018","journal-title":"Pediatr. Res."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1565","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14760584.2019.1675519","article-title":"Preexisting influenza specific immunity and vaccine effectiveness","volume":"18","author":"Jang","year":"2019","journal-title":"Expert Rev. Vaccines"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb1570","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/INF.0000000000002398","article-title":"Narcolepsy and pandemic influenza vaccination: what we need to know to be ready for the next pandemic","volume":"38","author":"Edwards","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb1575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (bell\u2019s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1580","article-title":"Better adjuvants for better vaccines: Progress in adjuvant delivery systems, modifications, and adjuvant-antigen Codelivery","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2025.115715_bb1585","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-065X.2003.00072.x","article-title":"Structure, lymphatic vascularization and lymphocyte migration in mucosa-associated lymphoid tissue","volume":"195","author":"Azzali","year":"2003","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1590","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/01926230600865531","article-title":"Normal structure, function, and histology of mucosa-associated lymphoid tissue","volume":"34","author":"Cesta","year":"2006","journal-title":"Toxicol. Pathol."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1595","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent Progress in Oral drug delivery Systems for Biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.addr.2025.115715_bb1600","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nri3007","article-title":"The light and dark sides of intestinal intraepithelial lymphocytes","volume":"11","author":"Cheroutre","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1605","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/1871530319666181128160411","article-title":"Development and Organization of the Secondary and Tertiary Lymphoid Organs: influence of microbial and food antigens","volume":"19","author":"Magrone","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1610","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4049\/jimmunol.1900710","article-title":"Dendritic cell subsets in intestinal immunity and inflammation","volume":"204","author":"Sun","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb1615","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2019.05.001","article-title":"How the gut microbiome regulates host immune responses to viral vaccines","volume":"37","author":"Vlasova","year":"2019","journal-title":"Curr. Opin. Virol."},{"issue":"28","key":"10.1016\/j.addr.2025.115715_bb1620","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.vaccine.2013.04.035","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits","volume":"31","author":"Kuschner","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1625","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7774\/cevr.2017.6.1.15","article-title":"The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants","volume":"6","author":"Kim","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb1630","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14760584.2020.1800459","article-title":"Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned","volume":"19","author":"Pereira","year":"2020","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1635","article-title":"Overview of the development, impacts, and challenges of live-attenuated Oral rotavirus vaccines","volume":"8","author":"Folorunso","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.addr.2025.115715_bb1640","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14712590903103787","article-title":"A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix","volume":"9","author":"Nakagomi","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2025.115715_bb1645","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpb.2015.09.018","article-title":"A lipid based multi-compartmental system: liposomes-in-double emulsion for oral vaccine delivery","volume":"97","author":"Liau","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1650","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1208\/s12249-019-1325-z","article-title":"Nanoparticles: Oral delivery for protein and peptide drugs","volume":"20","author":"Cao","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1655","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.cgh.2014.06.018","article-title":"Polymeric nanoparticle technologies for oral drug delivery","volume":"12","author":"Pridgen","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1660","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12033-019-00222-1","article-title":"Edible vaccines: promises and challenges","volume":"62","author":"Kurup","year":"2020","journal-title":"Mol. Biotechnol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1665","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/0929866526666191014151237","article-title":"Seeds as economical production platform for recombinant proteins","volume":"27","author":"Khan","year":"2020","journal-title":"Protein Pept. Lett."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216533","article-title":"Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-two randomized phase II clinical trials in 18 to 49 and \u226550 years old adults","volume":"14","author":"Pillet","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1675","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1680","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41423-021-00809-2","article-title":"Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates","volume":"19","author":"Pillet","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1685","article-title":"What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?","volume":"8","author":"Rosales-Mendoza","year":"2020","journal-title":"S"},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1690","doi-asserted-by":"crossref","first-page":"388","DOI":"10.18433\/jpps30528","article-title":"Overview and future potential of fast dissolving buccal films as drug delivery system for vaccines","volume":"22","author":"Uddin","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115715_bb1695","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2014.05.060","article-title":"Buccal and sublingual vaccine delivery","volume":"190","author":"Kraan","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115715_bb1700","first-page":"18","article-title":"Sublingual mucosa as a route for systemic drug delivery","volume":"3","author":"Narang","year":"2011","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.addr.2025.115715_bb1705","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3389\/fphar.2019.01328","article-title":"Advances in Nanoparticulate drug delivery approaches for sublingual and buccal administration","volume":"10","author":"Hua","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1710","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0030-4220(74)90430-7","article-title":"Effect of various conditions on the sublingual absorption of Para-aminosalicylic acid","volume":"37","author":"De Marco","year":"1974","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb1715","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/1947-2714.118923","article-title":"Langerhans cells and their role in oral mucosal diseases","volume":"5","author":"Upadhyay","year":"2013","journal-title":"N. Am. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1720","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/mp200392g","article-title":"A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs","volume":"9","author":"Choi","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb1725","first-page":"1","article-title":"Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues","volume":"354","author":"Czerkinsky","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1730","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2011.01.027","article-title":"Advances in oral transmucosal drug delivery","volume":"153","author":"Patel","year":"2011","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1735","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1601-0825.2005.01217.x","article-title":"The distribution of oral mucosal pH values in healthy saliva secretors","volume":"12","author":"Aframian","year":"2006","journal-title":"Oral Dis."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1740","first-page":"237","article-title":"Cellular and molecular basis of barrier function in oral epithelium","volume":"8","author":"Wertz","year":"1991","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1745","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1073\/pnas.0708684105","article-title":"Sublingual vaccination with influenza virus protects mice against lethal viral infection","volume":"105","author":"Song","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1750","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4110\/in.2013.13.6.275","article-title":"Mucosal immunization with recombinant adenovirus encoding soluble globular head of hemagglutinin protects mice against lethal influenza virus infection","volume":"13","author":"Kim","year":"2013","journal-title":"Immune Netw."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1755","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.1601775","article-title":"Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems","volume":"199","author":"Boyaka","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1760","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.coi.2011.03.009","article-title":"Defending the mucosa: adjuvant and carrier formulations for mucosal immunity","volume":"23","author":"Lawson","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"34","key":"10.1016\/j.addr.2025.115715_bb1765","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1016\/j.vaccine.2010.06.033","article-title":"Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract","volume":"28","author":"Hervouet","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb1770","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2015.11.006","article-title":"PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination","volume":"223","author":"Oberoi","year":"2016","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb1775","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.4161\/hv.32253","article-title":"Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system","volume":"10","author":"White","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb1780","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-014-9565-z","article-title":"Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine","volume":"16","author":"Murugappan","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2025.115715_bb1785","author":"Nitto Denko Corporation. Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers NCT number: NCT02955030. 2017 [cited"},{"issue":"5","key":"10.1016\/j.addr.2025.115715_bb1790","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/all.14113","article-title":"30 years of sublingual immunotherapy","volume":"75","author":"Passalacqua","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.addr.2025.115715_bb1795","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13601-015-0088-1","article-title":"Choosing the optimal dose in sublingual immunotherapy: rationale for the 300 index of reactivity dose","volume":"5","author":"Demoly","year":"2015","journal-title":"Clin. Transl. Allergy"},{"issue":"380","key":"10.1016\/j.addr.2025.115715_bb1800","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6413","article-title":"An oral microjet vaccination system elicits antibody production in rabbits","volume":"9","author":"Aran","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2025.115715_bb1805","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jconrel.2014.09.028","article-title":"Microprojection arrays to immunise at mucosal surfaces","volume":"196","author":"McNeilly","year":"2014","journal-title":"J. Control. Release"},{"issue":"35","key":"10.1016\/j.addr.2025.115715_bb1810","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1016\/j.vaccine.2015.03.081","article-title":"Multifunctional liposomes constituting microneedles induced robust systemic and mucosal immunoresponses against the loaded antigens via oral mucosal vaccination","volume":"33","author":"Zhen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb1815","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.colsurfb.2015.01.005","article-title":"Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain","volume":"126","author":"Wang","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2025.115715_bb1820","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2016.07.036","article-title":"Multi-layered nanofibrous mucoadhesive films for buccal and sublingual administration of drug-delivery and vaccination nanoparticles - important step towards effective mucosal vaccines","volume":"249","author":"Ma\u0161ek","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115715_bb1825","article-title":"Pandemics throughout history","volume":"11","author":"Piret","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2025.115715_bb1830","series-title":"Psychiatry of Pandemics: A Mental Health Response to Infection Outbreak","first-page":"7","article-title":"Brief history of pandemics (pandemics throughout history)","author":"Huremovi\u0107","year":"2019"},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1835","doi-asserted-by":"crossref","first-page":"202","DOI":"10.7774\/cevr.2024.13.3.202","article-title":"Insights into structural vaccinology harnessed for universal coronavirus vaccine development","volume":"13","author":"Lim","year":"2024","journal-title":"Clin Exp Vaccine Res"},{"issue":"16","key":"10.1016\/j.addr.2025.115715_bb1840","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1021\/acs.jctc.3c00513","article-title":"Computational methods in immunology and vaccinology: design and development of antibodies and immunogens","volume":"19","author":"Guarra","year":"2023","journal-title":"J. Chem. Theory Comput."},{"issue":"6510","key":"10.1016\/j.addr.2025.115715_bb1845","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"6483","key":"10.1016\/j.addr.2025.115715_bb1850","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6136","key":"10.1016\/j.addr.2025.115715_bb1855","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"6452","key":"10.1016\/j.addr.2025.115715_bb1860","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.addr.2025.115715_bb1865","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00058-19","article-title":"Influenza virus with increased pH of hemagglutinin activation has improved replication in cell culture but at the cost of infectivity in human airway epithelium","volume":"93","author":"Singanayagam","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2025.115715_bb1870","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101335","article-title":"Hemagglutinin stability as a key determinant of influenza a virus transmission via air","volume":"61","author":"Tosheva","year":"2023","journal-title":"Curr. Opin. Virol."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1875","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.vaccine.2018.01.045","article-title":"Influenza vaccine effectiveness in older adults compared with younger adults over five seasons","volume":"36","author":"Russell","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1880","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"issue":"4","key":"10.1016\/j.addr.2025.115715_bb1890","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2025.115715_bb1895","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107300","article-title":"Soft mist inhaler nebulization by Rayleigh-breakup largely preserves functional integrity of liposomal mRNA in respirable aerosols","author":"Biesel","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb1900","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03309-9","article-title":"Laminar fluid ejection device enables high yield and preservation of mRNA and SaRNA LNP formulations","volume":"15","author":"Ho","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115715_bb1905","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1456538","article-title":"Targeting aerosol delivery to regions of nasal-associated lymphoid tissue (NALT) in three dimensional models of human intranasal airways using the BiVax intranasal atomizer","volume":"4","author":"Laube","year":"2024","journal-title":"Front Drug Deliv."},{"key":"10.1016\/j.addr.2025.115715_bb1910","unstructured":"Media Relations, University of Waterloo (2021, November 2) Waterloo startup performs first ever robotic intramuscular injection https:\/\/uwaterloo.ca\/news\/media\/waterloo-startup-performs-first-ever-robotic-intramuscular (accessed 10\/6\/25)."},{"issue":"14","key":"10.1016\/j.addr.2025.115715_bb1915","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.3390\/s22145315","article-title":"InjectMeAI-software module of an autonomous injection humanoid","volume":"22","author":"Ampadu","year":"2022","journal-title":"Sensors (Basel)."},{"key":"10.1016\/j.addr.2025.115715_bb1920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther Nucleic Acids"},{"key":"10.1016\/j.addr.2025.115715_bb1925","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123695","article-title":"Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines","volume":"650","author":"Yang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb1930","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/v15081760","article-title":"Vaccines' New Era-RNA Vaccine","volume":"15","author":"Zhou","year":"2023","journal-title":"Viruses"},{"issue":"31","key":"10.1016\/j.addr.2025.115715_bb1935","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","article-title":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG","volume":"41","author":"Kozma","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb1940","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jconrel.2020.10.011","article-title":"Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice","volume":"329","author":"McSweeney","year":"2021","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.addr.2025.115715_bb1945","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1021\/acs.biomac.3c00649","article-title":"Zwitterionic polymer-decorated lipid nanoparticles for mRNA delivery in mammalian cells","volume":"24","author":"Khunsuk","year":"2023","journal-title":"Biomacromolecules"},{"issue":"11","key":"10.1016\/j.addr.2025.115715_bb1950","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","article-title":"Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery","volume":"3","author":"Nogueira","year":"2020","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.addr.2025.115715_bb1955","first-page":"86","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang","year":"2024","journal-title":"Bioact Mater"},{"issue":"6356","key":"10.1016\/j.addr.2025.115715_bb1960","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1126\/science.aaf7447","article-title":"Fabrication of fillable microparticles and other complex 3D microstructures","volume":"357","author":"McHugh","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1965","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002090","article-title":"Covalent organic frameworks for biomedical applications","volume":"10","author":"Esrafili","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2025.115715_bb1970","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125295","article-title":"Current landscape of metal-organic framework-mediated nucleic acid delivery and therapeutics","volume":"672","author":"Feng","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb1975","article-title":"Biomimetic functionalized metal organic frameworks as multifunctional agents: paving the way for cancer vaccine advances","volume":"27","author":"Tousian","year":"2024","journal-title":"Mater Today Bio."},{"issue":"6","key":"10.1016\/j.addr.2025.115715_bb1980","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1021\/acs.chemrev.3c00409","article-title":"The promise and potential of metal-organic frameworks and covalent organic frameworks in vaccine nanotechnology","volume":"124","author":"Wijesundara","year":"2024","journal-title":"Chem. Rev."},{"issue":"21","key":"10.1016\/j.addr.2025.115715_bb1985","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1039\/D3SC00500C","article-title":"In vivo biocompatibility of ZIF-8 for slow release via intranasal administration","volume":"14","author":"Kumari","year":"2023","journal-title":"Chem. Sci."},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb1990","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6380","article-title":"Zeolitic imidazolate frameworks activate endosomal toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer","volume":"10","author":"Alsaiari","year":"2024","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.addr.2025.115715_bb1995","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102313","article-title":"Advancements and challenges in mRNA and ribonucleoprotein-based therapies: from delivery systems to clinical applications","volume":"35","author":"Eftekhari","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb2000","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2025.115715_bb2005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jconrel.2016.10.003","article-title":"Non-invasive epicutaneous vaccine against respiratory syncytial virus: preclinical proof of concept","volume":"243","author":"Herv\u00e9","year":"2016","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.addr.2025.115715_bb2010","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.vaccine.2011.12.130","article-title":"Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria","volume":"30","author":"Hirobe","year":"2012","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.addr.2025.115715_bb2015","doi-asserted-by":"crossref","first-page":"33299","DOI":"10.1021\/acsami.3c03900","article-title":"Non-invasive transdermal delivery of antisense oligonucleotides with biocompatible ionic liquids","volume":"15","author":"Toyofuku","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"24","key":"10.1016\/j.addr.2025.115715_bb2020","doi-asserted-by":"crossref","first-page":"22424","DOI":"10.1021\/acsnano.5c06418","article-title":"Active chemical messenger-driven immune activation via electrochemical patch for in-situ tumor vaccination","volume":"19","author":"Zou","year":"2025","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb2025","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1021\/acsabm.5c01361","article-title":"Needle-free transdermal patch for influenza vaccination","volume":"8","author":"Tanaka","year":"2025","journal-title":"ACS Appl. Bio. Mater."},{"key":"10.1016\/j.addr.2025.115715_bb2030","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126699","article-title":"Vaccine microarray patch self-administration: a preliminary study in adults 50 years of age and over","volume":"48","author":"Davies","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2025.115715_bb2035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125874","article-title":"Formulation, sterilization, and clinical evaluation of microneedles for vaccine and biologic delivery: a review","volume":"682","author":"Sanjanwala","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb2040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125662","article-title":"Thermostabilization of a model viral-vectored oral thin, film vaccine","volume":"678","author":"Yardy","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115715_bb2045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jconrel.2024.01.062","article-title":"Oral mucosal vaccination using integrated fiber microneedles","volume":"367","author":"Creighton","year":"2024","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb2050","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/17425247.2023.2264189","article-title":"Microneedles for oral mucosal delivery - current trends and perspective on future directions","volume":"20","author":"Ferreira","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2025.115715_bb2055","article-title":"Edible vaccines: a paradigm shift in vaccine delivery and Global Health solutions","author":"Mehra","year":"2025","journal-title":"Curr. Drug Discov. Technol."},{"issue":"2","key":"10.1016\/j.addr.2025.115715_bb2060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/vaccines13020191","article-title":"Molecular farming for immunization: current advances and future prospects in plant-produced vaccines","volume":"13","author":"Vo","year":"2025","journal-title":"Vaccines (Basel)."},{"issue":"9","key":"10.1016\/j.addr.2025.115715_bb2065","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1021\/acsabm.5c00959","article-title":"Probiotic Bacteria as therapeutics and biohybrid drug carriers: advances, design strategies, and future outlook","volume":"8","author":"Sahoo","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"issue":"798","key":"10.1016\/j.addr.2025.115715_bb2070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh9906","article-title":"An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study","volume":"17","author":"Flitter","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2025.115715_bb2075","author":"General Assembly of the United Nations, Fifty-Fifth Session United Nations Millennium Declaration"},{"key":"10.1016\/j.addr.2025.115715_bb2080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126180","article-title":"Recent advances in vaccine adjuvants: from lab to clinic","volume":"684","author":"Vardikar","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb2085","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14760584.2023.2268724","article-title":"Mucosal vaccination: onward and upward","volume":"22","author":"Tsai","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2025.115715_bb2090","article-title":"Personalized immunization to optimize vaccine immunogenicity: exploring the multidimensional effects of host intrinsic factors, external intervention strategies, and the external environment","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2025.115715_bb2095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41541-025-01211-z","article-title":"De-risking vaccine development: lessons, challenges, and prospects","volume":"10","author":"Masignani","year":"2025","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.addr.2025.115715_bb2100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113794","article-title":"Dissolving microneedles in transdermal drug delivery: a critical analysis of limitations and translation challenges","volume":"383","author":"Moawad","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115715_bb2105","doi-asserted-by":"crossref","DOI":"10.1089\/jamp.2024.0058","article-title":"Inhalable and nasal biologics: analytical, formulation, development, and regulatory considerations","author":"Cipolla","year":"2025","journal-title":"J. Aerosol Med. Pulm Drug"},{"key":"10.1016\/j.addr.2025.115715_bb2110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2024.04.010","article-title":"Regulatory insights into nanomedicine and gene vaccine innovation: safety assessment, challenges, and regulatory perspectives","volume":"180","author":"Souto","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2025.115715_bb2115","series-title":"Regulatory Consideration and Pathways for Vaccine Development","first-page":"325","author":"Ahirwar","year":"2024"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:01:56Z","timestamp":1780549316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25002005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":423,"alternative-id":["S0169409X25002005"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115715","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composition, stabilization and delivery of virus-based vaccines: considerations to break free of the cold chain","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115715"}}